Question explored with the scientific record
What about vitamin k2 for reducing blood pressure
Vitamin K2 does not lower blood pressure. It changes a lab marker, not your numbers.
The retrieved evidence does not contain a single trial of vitamin K2 with blood pressure as an outcome. What it contains is vitamin K2 studies measuring something else entirely: in hemodialysis patients, MK-7 at 360, 720, and 1080 micrograms dropped dp-ucMGP by 17%, 33%, and 46% respectively [1]. That marker reflects vitamin K status in the vessel wall, not pressure. In kidney transplant recipients, MK-7 360 micrograms daily cut dp-ucMGP by 55% and arterial stiffness improved in association with that drop [1]. Arterial stiffness is not blood pressure, and association is not causation. The one randomized trial in type 2 diabetics with cardiovascular disease found no significant change in calcification score after 24 weeks of MK-7 [1]. The review itself concludes there is no conclusive evidence K2 slows vascular calcification [1].
The blood pressure data that does exist is for other vitamins, and it is mixed. Vitamin D lowered systolic pressure in hypertensive subgroups but not overall [5], and a separate randomized trial in hypertensive patients with low vitamin D found no blood pressure effect at all, while triglycerides rose [4]. Vitamin C at 500 mg daily for five years did not lower pressure; systolic actually rose in every group [3]. A combined vitamin C, E, and folate trial did drop systolic by about 7 points in young healthy men [2], but that is a different intervention than the one you asked about.
| Intervention | Population | Systolic BP effect |
|---|---|---|
| MK-7 (K2) | Dialysis, transplant | Not measured [1] |
| MK-7 (K2) | Diabetics with CVD | No calcification change [1] |
| Vitamin D | Hypertensive, deficient | No overall effect [5] |
| Vitamin C 500 mg, 5 yr | High-risk Japanese | Rose ~5.9 mmHg [3] |
My call: there is no evidence here that vitamin K2 reduces blood pressure, and the mechanism people cite, arterial stiffness, was never tested against pressure in these records. If your goal is lower blood pressure, K2 is not the tool the evidence supports. Confidence: moderate that K2 does not lower blood pressure, based on absence of any trial measuring it and the null vascular findings that do exist.
Sources used 5
-
Role of Vitamin K in CKD: Is Its Supplementation Advisable in CKD Patients?
Vitamin K deficiency is common in CKD; supplementation with vitamin K2 lowers dp-ucMGP but there is no conclusive evidence that it slows vascular calcification or reduces CKD-related bone complications, underscoring the need for robust randomized trials.
DOI: 10.1159/000516611 -
Cardiovascular Effects of Oral Supplementation of Vitamin C, E and Folic Acid in Young Healthy Males
Daily supplementation with vitamin C (1000 mg), vitamin E (800 mg), and folic acid (10 mg) for 12 weeks reduces systolic blood pressure in healthy young men under highly controlled measurement, with limited or no consistent changes in other vascular function markers.
DOI: 10.1024/0300-9831.74.4.285 -
Lack of Long-Term Effect of Vitamin C Supplementation on Blood Pressure
This study found that long-term vitamin C supplementation (50 mg or 500 mg daily for 5 years) did not significantly reduce blood pressure in a high-risk Japanese population with atrophic gastritis, with systolic blood pressure actually increasing in all groups over the study per…
DOI: 10.1161/01.hyp.0000038339.67450.60 -
Effects of Vitamin D on Blood Pressure and Cardiovascular Risk Factors
This randomized controlled trial evaluated the effects of vitamin D supplementation on blood pressure and cardiovascular risk factors in hypertensive patients with low vitamin D levels, finding no significant impact on blood pressure but a notable increase in triglycerides.
DOI: 10.1161/hypertensionaha.115.05319 -
The effect of vitamin D3 on blood pressure in people with vitamin D deficiency
Oral vitamin D3 has no significant overall effect on systolic or diastolic blood pressure in vitamin D deficient adults, though subgroups with hypertension, age over 50 years, or BMI over 30 show reduced systolic pressure.
DOI: 10.1097/md.0000000000015284